Scribd
Upload
51 views2 pages

I Don't Think There's A Limit To The Type of Tumor We Could Potentially Treat, As Long As It Has Been Infiltrated by The Immune System

Uploaded by

markzucker

Researchers at Stanford treated tumors in mice using a combination of two agents that stimulated the mice's immune systems. They found that treating the first tumor that arose prevented future tumors and increased lifespan. Additionally, treating one lymphoma tumor caused regression of another lymphoma tumor in a different location but did not affect a colon cancer, showing the treatment's specificity. The researchers believe this targeted immune system approach could work for many tumor types as long as the tumor is infiltrated by the immune system. A current clinical trial is testing this treatment approach in humans with lymphoma.

Copyright:

© All Rights Reserved
Download as DOCX, PDF, TXT or read online from Scribd
Download as docx, pdf, or txt

I Don't Think There's A Limit To The Type of Tumor We Could Potentially Treat, As Long As It Has Been Infiltrated by The Immune System

Uploaded by

markzucker
51 views2 pages
Researchers at Stanford treated tumors in mice using a combination of two agents that stimulated the mice's immune systems. They found that treating the first tumor that arose prevented future tumors and increased lifespan. Additionally, treating one lymphoma tumor caused regression of another lymphoma tumor in a different location but did not affect a colon cancer, showing the treatment's specificity. The researchers believe this targeted immune system approach could work for many tumor types as long as the tumor is infiltrated by the immune system. A current clinical trial is testing this treatment approach in humans with lymphoma.

Original Title

bnhy

Copyright

© © All Rights Reserved

Available Formats

DOCX, PDF, TXT or read online from Scribd

Did you find this document useful?

Is this content inappropriate?

Researchers at Stanford treated tumors in mice using a combination of two agents that stimulated the mice's immune systems. They found that treating the first tumor that arose prevented future tumors and increased lifespan. Additionally, treating one lymphoma tumor caused regression of another lymphoma tumor in a different location but did not affect a colon cancer, showing the treatment's specificity. The researchers believe this targeted immune system approach could work for many tumor types as long as the tumor is infiltrated by the immune system. A current clinical trial is testing this treatment approach in humans with lymphoma.

Copyright:

© All Rights Reserved
Download as DOCX, PDF, TXT or read online from Scribd
Download as docx, pdf, or txt
51 views2 pages

I Don't Think There's A Limit To The Type of Tumor We Could Potentially Treat, As Long As It Has Been Infiltrated by The Immune System

Uploaded by

markzucker
Researchers at Stanford treated tumors in mice using a combination of two agents that stimulated the mice's immune systems. They found that treating the first tumor that arose prevented future tumors and increased lifespan. Additionally, treating one lymphoma tumor caused regression of another lymphoma tumor in a different location but did not affect a colon cancer, showing the treatment's specificity. The researchers believe this targeted immune system approach could work for many tumor types as long as the tumor is infiltrated by the immune system. A current clinical trial is testing this treatment approach in humans with lymphoma.

Copyright:

© All Rights Reserved
Download as DOCX, PDF, TXT or read online from Scribd
Download as docx, pdf, or txt
You are on page 1/ 2

treatment.

The researchers saw similar results in mice bearing breast, colon and melanoma
tumors.
I don’t think there’s a limit to the type of tumor we could potentially treat, as long as it has been infiltrated by the
immune system.

Mice genetically engineered to spontaneously develop breast cancers in all 10 of their mammary
pads also responded to the treatment. Treating the first tumor that arose often prevented the
occurrence of future tumors and significantly increased the animals’ life span, the researchers
found.
Finally, Sagiv-Barfi explored the specificity of the T cells by transplanting two types of tumors into
the mice. She transplanted the same lymphoma cancer cells in two locations, and she
transplanted a colon cancer cell line in a third location. Treatment of one of the lymphoma sites
caused the regression of both lymphoma tumors but did not affect the growth of the colon cancer
cells.
“This is a very targeted approach,” Levy said. “Only the tumor that shares the protein targets
displayed by the treated site is affected. We’re attacking specific targets without having to identify
exactly what proteins the T cells are recognizing.”
The current clinical trial is expected to recruit about 15 patients with low-grade lymphoma. If
successful, Levy believes the treatment could be useful for many tumor types. He envisions a
future in which clinicians inject the two agents into solid tumors in humans prior to surgical
removal of the cancer as a way to prevent recurrence due to unidentified metastases or lingering
cancer cells, or even to head off the development of future tumors that arise due to genetic
mutations like BRCA1 and 2.
“I don’t think there’s a limit to the type of tumor we could potentially treat, as long as it has been
infiltrated by the immune system,” Levy said.
The work is an example of Stanford Medicine’s focus on precision health, the goal of which is to
anticipate and prevent disease in the healthy and precisely diagnose and treat disease in the ill.
The study’s other Stanford co-authors are senior research assistant and lab manager Debra
Czerwinski; professor of medicine Shoshana Levy, PhD; postdoctoral scholar Israt Alam, PhD;
graduate student Aaron Mayer; and professor of radiology Sanjiv Gambhir, MD, PhD.
Levy is a member of the Stanford Cancer Institute and Stanford Bio-X.
Gambhir is the founder and equity holder in CellSight Inc., which develops and translates
multimodality strategies to image cell trafficking and transplantation.
The research was supported by the National Institutes of Health (grant CA188005), the Leukemia
and Lymphoma Society, the Boaz and Varda Dotan Foundation and the Phil N. Allen Foundation.
Stanford’s Department of Medicine also supported the work.

 PRESS RELEASES 

ByKRISTA CONGER
Krista Conger is a science writer in the Office of Communications. Email her
at [email protected].

You might also like